Rxsight Inc at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Really happy to have RxSight as our next presentation. CEO, Ron Kurtz will do a presentation followed by some Q&A. Ron?
Thank you, Robbie. Appreciate being here again this year. These are our forward-looking statements. RxSight is focused on transforming cataract surgery outcomes via the power of adjustability, and adjustability is a new capability that hasn't existed in ophthalmology. We pioneered that over the last 5 years, and I'll talk a little bit about how that is transforming cataract surgery and particularly, premium IOLs.
If we take a snapshot of RxSight today, over the past five years, we've grown to about 500 employees. We've performed about 300,000 LAL procedures. We have -- we're in about 1,100 ophthalmic offices with our piece of equipment that does the adjustment, the Light Delivery Device. We've trained over 2,500 surgeons and attained a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
